CYAD
Celyad Oncology S.A.
Set alert
52-week range unavailable
- Open
- 0.52
- Prev close
- 0.47
- Mkt cap
- 14.24M
- Vol
- 49.00K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.47
- High
- 0.528
- Forward P/E
- -0.11
- Beta
- 1.69
- Short ratio
- 11.46
- Inst. own
- 29.15%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 23, 2023
- 50-d avg
- 0.662867
- 200-d avg
- 1.07
- 1y target
- 8.52
Key statistics
- Market cap
- 14.24M
- Enterprise value
- -1.57M
- Trailing P/E
- 0.00
- Forward P/E
- -0.11
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.46
- EPS (TTM)
- -1.47
- Beta
- 1.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -10.59M
- Total cash
- 12.45M
- Total debt
- 255.00K
- Return on equity
- -170.72%
- Shares outstanding
- 22.59M
- Short % of float
- 0.00%
- 50-day average
- 0.662867
- 200-day average
- 1.07
Analyst view
Consensus: hold
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 23, 2023
Expected Mar 23, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 23, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Mar 24, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Mar 24, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Mar 24, 2020 | Dec 1, 2019 | 0.00 | — | — | — |
| Mar 28, 2019 | Dec 1, 2018 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 11, 2022 | Wells Fargo | main | — | Overweight |
| Aug 6, 2021 | HC Wainwright & Co. | main | — | Buy |
| May 10, 2021 | HC Wainwright & Co. | main | — | Buy |
| Mar 26, 2021 | JonesTrading | down | Buy | Hold |
| Dec 8, 2020 | HC Wainwright & Co. | main | — | Buy |
| Mar 26, 2020 | Wells Fargo | main | — | Overweight |
About Celyad Oncology S.A.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Belgium
- Website
- celyad.com
News
- Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
- Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
- Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
- Celyad Oncology announces receipt of Nasdaq delisting notice
- Celyad Oncology reports first quarter 2023 financial results and recent business highlights
- Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
- Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
- Celyad Oncology announces receipt of Nasdaq notice
- Celyad Oncology appoints Georges Rawadi as its new CEO
- Celyad Oncology reports full year 2022 financial results and recent business highlights
Your note
Sign in to keep a note on CYAD — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fortress Investment Group LLC | 28.77% | 6,500,000 | 3.05M | Mar 30, 2023 |
| Citadel Advisors Llc | 0.07% | 16,285 | 7.65K | Mar 30, 2023 |
| Two Sigma Securities, LLC | 0.05% | 11,032 | 5.18K | Mar 30, 2023 |
| National Bank of Canada/FI | 0.02% | 3,400 | 1.60K | Mar 30, 2023 |
| UBS Group AG | 0.01% | 2,124 | 998 | Mar 30, 2023 |
| Wells Fargo & Company | 0.00% | 570 | 267 | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,012 | 945 | Feb 27, 2023 |